INTRODUCTION

Top Abstract Introduction Materials & Methods Results Discussion References

The alternative complement pathway (ACP) is a primary host defense system that can be triggered by a wide variety of bacteria, parasites, virus-infected cells, and tumor cells. In contrast to the classical pathway, which relies on immunoglobulins or other recognition molecules, the ACP performs a constant surveillance function that does not depend on acquired immunity. Continuous low-grade interaction of C3 and factors B, D, and P cleaves C3 to C3a and C3b (34, 35). The nascent C3b that is generated contains a reactive thioester which can bind covalently to cell surfaces (16). Activation of the ACP is achieved following formation of the critical C3 convertase enzyme, C3bBb, which generates additional C3b in a positive feedback loop. The result is opsonization for clearance by phagocytic cells bearing C3 receptors and/or formation of the lytic membrane attack complex.

Normal human cells and tissues have specific regulatory proteins that block complement activation by inhibiting the formation of C3bBb and by promoting the breakdown of the convertase and C3b (2). These proteins share structural and functional characteristics and are encoded by a gene cluster termed the regulators of complement activation locus (13). The genes in this cluster encode serum factor H and C4b binding protein, as well as the cell surface-associated decay-accelerating factor (DAF), membrane cofactor protein (MCP), and complement receptors CR1 and CR2. DAF and MCP are responsible for protecting host cells from autologous complement-mediated attack. They have wide tissue distributions and function intrinsically by destabilizing C3 convertases (DAF) or by serving as cofactors for the cleavage of deposited C3b by factor I (MCP) (17, 26, 27, 37). CR1 and CR2 have more limited tissue distributions and function extrinsically as receptors for C3b/C4b (CR1) or C3dg (CR2) deposited on complement activators (1). Since in general foreign cells do not possess C3 regulatory molecules, these proteins provide a mechanism for distinguishing self from non-self (2).

Factor H is the principal serum regulator of the ACP. It inhibits convertase formation both in the fluid phase and on cells by binding C3b in place of factor B and acting as a cofactor for C3b cleavage. With respect to C3b on cells, H is capable of discriminating human cells and pathogens by virtue of exhibiting higher affinity for bound C3b when it jointly recognizes sialic acid or polyanions on human cell surfaces (6, 15, 20). The ability to decrease H affinity for C3b and thereby activate the ACP has been demonstrated with microbial cell wall polysaccharides, such as zymosan and bacterial lipopolysaccharide (LPS), consistent with the role of restricted H function in ACP-mediated defense (7, 33).

Complement regulatory function on human cells can be restricted and human cells can be converted to activators of the ACP by virus infection or malignant transformation. For example, some human lymphoid cell lines have been shown to activate the ACP in human serum despite the presence of membrane DAF and MCP (5). Activation of the ACP by viral glycoproteins expressed on infected cells has also been demonstrated (24). Three previous reports have provided evidence that DAF, like H, has reduced regulatory activity on some surfaces which activate the ACP (22, 25, 31). However, the mechanism by which DAF activity is overcome on ACP activators is unknown.

Studies by Pangburn (29, 30) of C3b in the fluid phase have established that occupancy of the C3 covalent binding site by acceptor groups in certain polysaccharides can decrease H binding. More recently, analysis of deletion mutants of H has identified at least three sites on H that can promote its attachment to C3b on sheep erythrocytes (38). These authors reported that H binding to C3b on zymosan was less sensitive to deletion of two of these sites, suggesting that the lack of participation of these additional binding sites may account for the decreased affinity of H for C3b bound to ACP activators. Our previous studies indicate that DAF remains functional in the presence of phospholipid ACP activators but is a poor regulator of ACP activation by LPS (25). Binding of C3b to structures such as viral glycoproteins at a distance from the cell membrane might decrease the regulatory activity of membrane-bound DAF.

This study was undertaken to compare the regulatory activities of DAF and H on membranes containing ACP activators. A liposome model was used to compare regulation of C3bBb on membranes containing LPS molecules differing in length as prototypic polysaccharide activators and on membranes containing phospholipids which activate the ACP. The results indicate differences in restriction of H and DAF function by ACP activators, consistent with the concept that these regulators have complementary roles in the regulation of complement activation on cell membranes.

	MATERIALS AND METHODS

Top Abstract Introduction Materials & Methods Results Discussion References

Buffers. The following buffers were used: VBS (5 mM Veronal, 0.15 M NaCl [pH 7.4]), GVB (VBS containing 0.1% gelatin), GVB-Ni (GVB containing 1 mM NiCl₂), GGVB (GVB diluted with an equal volume of 5% glucose), and PBS (phosphate-buffered saline; 10 mM phosphate buffer, 0.15 NaCl [pH 7.4]).

Preparation of liposomes. Materials used for the preparation of liposomes were synthetic dipalmitoylphosphatidylcholine (DPPC; Sigma, St. Louis, Mo.), dipalmitoylphosphatidylethanolamine (DPPE) and cholesterol (CHOL) (Calbiochem, La Jolla, Calif.), and phenol-extracted LPS from wild-type and mutant (Re595, R7, and R5) serotypes of Salmonella minnesota and wild-type Salmonella typhosa. Lipids were dissolved in chloroform at 10 mM and stored under nitrogen at 20°C.

Quantitation of available LPS on liposomes. LPS at 1 mg/ml in 100 µl of VBS was mixed with an equal amount of Immunopure photoactivatable biotin (Pierce Chemical, Rockford, Ill.) in the dark. Mixtures were irradiated with three pulses of a Vivitar photoflash to induce cross-linking, incubated for 15 min on ice, and then dialyzed against VBS. The biotin-labeled LPS was serially diluted from 0.05 mg/ml in VBS, and 100-µl standards were incubated on microtiter wells overnight at 4°C. The wells were blocked with 0.5% bovine serum albumin (BSA) in PBS and developed with horseradish peroxidase (HRP)-conjugated streptavidin (BRL Life Technologies, Gaithersburg, Md.) diluted 1/1,000 in 0.1% BSA in PBS and ABTS [2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid)] substrate (1 mg of ABTS per ml and 0.01% H₂O₂ in citrate-phosphate buffer [pH 4.6]). Liposome samples to be tested were prepared as described above except that 25% of the total LPS used was biotin labeled. After preparation, duplicate 50-µl samples of each liposome preparation were pelleted by centrifugation and incubated for 1 h at room temperature in 100 µl of HRP-streptavidin. Liposomes were transferred to new tubes, washed three times with 1 ml of VBS, and incubated with 100 µl of ABTS substrate. All reactions were stopped after 1 h by adding 50 µl of 0.25 M oxalic acid. Liposomes were pelleted, supernatants were transferred to enzyme-linked immunosorbent assay (ELISA) plates containing the corresponding LPS standards, and the absorbance at 405 nm was determined. The concentration of LPS exposed on liposomes was calculated from standards after subtraction of values for nonlabeled liposome controls.

Preparation of complement reagents. Normal human serum (NHS) was obtained by centrifugation of blood collected from healthy adult volunteers and stored in aliquots at 70°C. To inhibit activation of the classical pathway, NHS was treated for 5 min on ice with 10 mM EGTA and 2.5 mM MgCl₂ (MgEGTA). To inhibit both pathways of activation, NHS was treated with 10 mM EDTA.

Complement activation by liposomes. Liposomes (20 µl at 10 mM phospholipid in VBS) were incubated in a 60-µl reaction mixture containing 20 µl of MgEGTA-treated NHS and 20 µl of GVB for 30 min at 37°C. Reactions were carried out in duplicate, and control samples were incubated in EDTA-treated NHS to assess nonspecific C3 binding, which was subtracted. The liposomes were washed three times in 1 ml of cold GVB and lysed with 150 µl of 0.5% Triton X-100 in PBS. Liposome samples were tested for C3 deposition by using a competitive ELISA as previously described (23).

C3 convertase inhibition by DAF. In these experiments the Ni²⁺-stabilized convertase was used to deposit C3b (8). All liposome types (4 µmol of phospholipid washed in GVB-Ni) were precoated with equal levels of bound C3b by incubation in 150 µl of preformed convertase solution (1 mg of C3 per ml, 0.6 mg of B per ml, 16 µg of D per ml, and 8 mM NiCl₂ in VBS, incubated for 5 min at room temperature) and C3 (0.1 mg/µmol of phospholipid) for 30 min at 37°C. Control liposomes were incubated in 150 µl of GVB in place of convertase to assess nonspecific C3 binding. Aliquots (400 nmol of phospholipid) were analyzed by competitive ELISA for bound C3, and the amount of C3b deposition on sample liposomes was determined by subtracting C3 binding on controls.

C3 convertase inhibition by H. Liposomes were prepared with equal amounts of bound C3b as described above. The ability of increasing H concentrations to regulate C3 deposition on liposomes by the ACP C3 convertase was determined as described for DAF except that H was added at the same time as convertase components and ¹²⁵I-C3.

H cofactor activity. Phosphatidylcholine (PC)-containing liposomes (PC liposomes) and LPS liposomes with bound ¹²⁵I-C3b were prepared by a three-step procedure. In the first step, liposomes containing 1.6 µmol of DPPC were washed with 1 ml of GVB-Ni and incubated for 30 min at 37°C in a 60-µl reaction volume containing 0.15 mg of C3/µmol of DPPC and 20 µl of preformed convertase (0.65 mg of C3 per ml, 0.42 mg of B per ml, 10.6 µg of D per ml, 40.6 µg of P per ml, and 5 mM NiCl₂ in VBS, incubated for 5 min at room temperature). In the second and third steps, liposomes were washed with 1 ml of GVB-Ni and reincubated for 30 min at 37°C in 300 µl of GGVB with 0.15 mg of ¹²⁵I-C3/µmol of DPPC (6 × 10⁶ cpm) and 0.1 mg of B per ml, 5 µg of D per ml, 30 µg of P per ml, and 5 mM NiCl₂. Following the third incubation, the ¹²⁵I-C3b liposomes were washed three times in 1 ml of GVB and adjusted to 10 mM DPPC in VBS. The ¹²⁵I-C3b liposomes were divided into 20-µl samples and incubated for 45 min at 37°C with increasing concentrations of H and 0.5 µg of factor I per ml in a volume of 30 µl. Reaction mixtures were boiled for 10 min in 25 µl of reducing sample buffer (0.125 M Tris [pH 6.8], 4% sodium dodecyl sulfate [SDS], 20% glycerol, 10% 2-mercaptoethanol, 0.001% bromophenol blue) and subjected to SDS-polyacrylamide gel electrophoresis (PAGE) on 5 to 15% gels. Gels were dried and analyzed by using a PhosphorImager and ImageQuant software (Molecular Dynamics, Sunnyvale, Calif.). The percent C3b cleaved was calculated from the ratio of the 68-kDa iC3b band divided by the sum of the 101-kDa C3b band and the 68-kDa iC3b band (36). Samples incubated with H or I only showed no cleavage of C3b.

Assay for DAF in liposomes. The level of DAF incorporation into liposomes was determined by using a direct ELISA. Microtiter wells were coated overnight at 4°C with DAF standards diluted in VBS. Wells were blocked with 0.5% BSA in PBS and incubated for 1 h with anti-DAF monoclonal antibody IA10 at 10 µg/ml in 0.1% BSA in PBS. ELISA wells were developed with HRP-conjugated rabbit anti-mouse immunoglobulin G (Cappel, Durham, N.C.) and ABTS substrate. Liposomes containing 300 nmol of phospholipid in VBS were pelleted and incubated sequentially with monoclonal antibody IA10, secondary antibody, and ABTS substrate as described above except in microcentrifuge tubes. After the final incubation, liposomes were pelleted and the absorbance at 405 nm of supernatants was determined after transfer to ELISA plates. Reactions were carried out in duplicate and in parallel with control liposomes.

	RESULTS

Top Abstract Introduction Materials & Methods Results Discussion References

ACP activation by liposomes. SM LPS and ST LPS (LPS from wild-type S. minnesota and S. typhosa, respectively) from smooth strains consist of a hydrophobic lipid A domain covalently linked to a conserved core oligosaccharide and a unique O antigen that may be repeated from 1 to 40 times (Fig. 1). These forms of LPS together with LPS from rough mutant strains of S. minnesota (Re595, R7, and R5) provided a series of LPS types differing in polysaccharide length which could be incorporated into membranes through their hydrophobic lipid A domains (10). Lipid vesicles of DPPC and CHOL were prepared with or without 12.5 µg of LPS per µmol of phospholipid and tested for ACP activation in MgEGTA-chelated serum (Fig. 2). The amount of LPS on liposome surfaces was approximately equal to the amount of LPS added during liposome preparation. As shown in Fig. 2, liposomes containing either SM, ST, R5, or R7 LPS activated the ACP, whereas liposomes containing Re595 LPS and control PC liposomes did not. ACP activation by the various LPS liposomes is consistent with previous results obtained by using micellular aggregates of LPS (40). As previously reported, liposomes containing 40% PE also activated the ACP (Fig. 2).

View larger version (24K): [in this window] [in a new window]   FIG. 1.   Structures of S. minnesota LPS (40) and general structure of S. typhosa LPS. Abbreviations: Gal, galactose; Glc, glucose; GlcNac, N-acetylglucosamine; GlcOAc, O-acetylglucose; Hep, L-glycero-D-mannoheptose; KDO, 3-deoxy-D-manno-octulosonic acid; Tyv, tyvelose; Rha, rhamnose; Man, mannose; P-OEtNH2, phosphoethanolamine; P, phosphate (n = 1 to 40).

View larger version (28K): [in this window] [in a new window]   FIG. 2.   ACP activation by liposomes containing LPS or PE. PC control liposomes were prepared with 2:1 molar ratios of DPPC and CHOL. LPS liposomes were prepared by addition of 12.5 µg of LPS of the indicated serotype/µmol of phospholipid. PE liposomes were prepared with 6:4:5 molar ratios of DPPC, DPPE, and CHOL. Liposomes (200 nmol of phospholipid) were incubated with MgEGTA-treated NHS, and C3 binding was measured by ELISA. Data presented are the mean ± SEM from three or more experiments.

Effect of DAF and H on ACP activation by LPS. C3, B, and D were used to deposit equal amounts of C3b (51 ± 6 ng of C3b/µmol of phospholipid) on liposomes containing mutant and wild-type LPS. DAF was then incorporated, and its ability to inhibit C3bBb activity was determined. The amount of DAF incorporated did not differ significantly among the different liposome types. The results illustrated in Fig. 3 demonstrate that DAF regulatory activity was reduced when R5, R7, or SM LPS was present in the membrane. In contrast, DAF activity was not affected by the addition of the nonactivating Re595 LPS, which has a lipid A moiety identical to that of the other LPS molecules. The inhibition of C3 convertase activity by DAF at 1.5 µg/ml was significantly decreased on R5, R7, or SM LPS liposomes compared to PC or Re595 LPS liposomes (P < 0.05).

View larger version (22K): [in this window] [in a new window]   FIG. 3.   Effect of LPS on DAF regulation of ACP C3 convertase activity. Liposomes with equal amounts of bound C3b were incubated with DAF to allow incorporation, washed, and incubated with 125I-C3, B, D, and NiCl2 to form the ACP C3 convertase. Inhibition of convertase activity by DAF was determined as the percent decrease in bound 125I-C3b observed in the presence of DAF. Results are the means ± SEM from two experiments using triplicate samples. t tests on the 1.5-µg/ml DAF values indicate that DAF inhibition of the C3 convertase did not differ on the PC and Re595 liposomes but that DAF inhibition was significantly less when R5, R7, or SM LPS liposomes were used (P < 0.05).

View larger version (21K): [in this window] [in a new window]   FIG. 4.   Effect of LPS on H regulation of ACP C3 convertase activity. Liposomes with equal amounts of bound C3b were incubated with 125I-C3, B, D, and NiCl2 to form the ACP C3 convertase in the presence and absence of H. Inhibition of convertase activity by H was determined as the percent decrease in bound 125I-C3b observed in the presence of H. Results are the means ± SEM from two or more experiments with triplicate samples. t tests on the 2.4-µg/ml H values indicate that H inhibition of the C3 convertase was significantly greater for PC or Re595 LPS liposomes than for SM LPS liposomes (P < 0.05). H inhibition of liposomes prepared with R5 and R7 LPS was intermediate and not significantly different from H inhibition of either PC or SM LPS liposomes.

Effect of LPS on the cofactor function of H. In the previous assay, H inhibition could have occurred on fluid-phase as well as liposome-bound C3b. To eliminate this possibility and to further examine the effect of LPS on H, the cofactor activity of H for factor I cleavage of C3b was determined on liposomes containing LPS. Liposomes containing ST, SM, R5, R7, or Re595 LPS or no LPS were prepared, and equal amounts of ¹²⁵I-C3b (32 ng/µmol of phospholipid) were deposited by incubation with C3, B, D, and P. The ¹²⁵I-C3b liposomes were then incubated with increasing concentrations of H and 0.5 µg of I per ml followed by SDS-PAGE on 5 to 15% gels under reducing conditions. H cofactor activity was determined by quantitating the amount of C3b cleaved to iC3b with a PhosphorImager. Figure 5A shows the results from a representative set of experiments with different concentrations of H. The results indicate that despite the presence of equal amounts of C3b, a greater amount of C3b was cleaved on PC, Re595, and R7 liposomes than on liposomes containing R5, SM, or ST LPS. Figure 5B shows the mean ± standard error of the mean (SEM) from three separate experiments for the percentage of cleaved C3b at the highest H concentration. Consistent with the results of the convertase inhibition assay, a greater fraction of C3b sites were resistant to H and I on R5 and wild-type LPS liposomes than on control PC liposomes or liposomes containing the shortest mutant LPS (Re595 and R7 LPS).

View larger version (27K): [in this window] [in a new window]   FIG. 5.   Cofactor activity of H for factor I cleavage of C3b on liposomes. (A) Liposomes with equal amounts of bound 125I-C3b were incubated with increasing concentrations of H in the presence of 0.5 µg of factor I per ml. Reaction mixtures were separated by SDS-PAGE on 5 to 15% gels under reducing conditions. Radioactive bands were analyzed with a PhosphorImager to determine the amount of C3b cleaved to iC3b. The percent C3 cleaved was determined from the quantity of 68-kDa iC3b  chain divided by the sum of the 68-kDa  chain and the 101-kDa C3b  chain. Less than 2% C3b cleavage was observed in the absence of H. Results of single experiments for each liposome type are shown. (B) Percentage of C3b cleaved on liposomes by I (0.5 µg/ml) in the presence of the maximum H concentration (33.3 µmol/mol of phospholipid). The level of C3b cleaved on liposomes was determined as described for panel A. Results presented are the mean ± SEM for three experiments. *, mean value significantly different from that for PC control liposomes (P < 0.05).

Effect of phospholipids on DAF and H. The addition of PE converts nonactivating PC liposomes to vesicles capable of activating the ACP (Fig. 2). Previous studies have shown that this activation is associated with decreased binding of H to C3b on the liposomes (23) but that DAF can regulate this activation in the presence of H in serum (25). Based on these results, it was of interest to compare the effect of PE directly on DAF and H regulation, using the purified ACP convertase. In convertase inhibition assays, whereas DAF behaved with equivalent efficiency in PC and PE liposomes (Fig. 6B), H was less effective on PE liposomes (Fig. 6A).

View larger version (12K): [in this window] [in a new window]   FIG. 6.   Effect of phospholipid composition on H and DAF regulation of ACP C3 convertase activity. PC and PE liposomes were prepared as for Fig. 1. (A) Liposomes with equal amounts of bound C3b were tested for inhibition of C3 convertase activity by DAF as described for Fig. 3. (B) Liposomes with equal amounts of bound C3b were tested for inhibition of C3 convertase activity by H as described for Fig. 4. Data presented are the means ± SEM of two or more experiments using triplicate samples.

	DISCUSSION

Top Abstract Introduction Materials & Methods Results Discussion References

Activation of the ACP depends on a positive feedback mechanism in which bound C3b interacts with B and D to form the C3 convertase, C3bBb. The specificity of this system resides in the selective inability of complement regulatory proteins to prevent formation of the C3 convertase on foreign or altered host cell surfaces. H is the primary regulator of the ACP which functions in serum, and the relative affinity of H for bound C3b is a major determining factor in ACP activation on surfaces (6, 7, 15, 33). The affinity of H for C3b is increased when C3b is bound to surfaces with sialic acid or other polyanions due to one or more polyanion binding sites on H (3, 20, 32, 38). The affinity of H for C3b is lower when C3b is bound to ACP activators such as zymosan or LPS (30, 33). DAF and MCP are found on most host cell membranes and are involved in preventing complement activation by host cells physiologically (17, 27). The role of these membrane regulatory proteins in ACP activation by altered host cells is less clear. In this report, the functional activities of DAF and factor H were compared in assays using liposomes modified to activate the ACP by the addition of various structurally defined LPS molecules or phospholipid. The results indicate that there are distinct differences in the effectiveness of the two regulatory proteins in the presence of different types of ACP-activating molecules.

DAF is a 70-kDa cell surface protein which functions to protect host tissue from autologous complement activation by destabilizing both classical and alternative pathway C3 convertases, C4b2a and C3bBb (9, 26). DAF functions only intrinsically and is attached to the cell surface via a C-terminal glycophosphatidylinositol (GPI) anchor (19, 41). A key property of GPI-anchored proteins is their ability when purified to reintegrate into lipid bilayers (18) and, once reintegrated, to function comparably to endogenously expressed proteins (17). While DAF normally acts in the context of other integral membrane proteins, studies using pure lipid vesicles have indicated that DAF functions independently of other membrane proteins to accelerate the decay of the ACP C3 convertase (25).

It has also been shown that ACP activation in serum by liposomes containing LPS is poorly regulated by DAF (25). Others have reported reduced DAF regulation of C3bBb on the human ACP activators, zymosan and rabbit and guinea pig erythrocytes (21, 31). On the other hand, DAF apparently lacks the polyanion-binding ability of H (31), and DAF activity was not increased in membranes containing sialated glycoproteins (25). Inhibitory effects of membrane constituents on DAF activity are suggested by the ability of transformed cells and cells expressing viral glycoproteins to activate the ACP despite the presence of DAF and MCP (5, 24). It is possible that difference in the interaction of C3bBb on ACP activators with DAF as well as H functions as a mechanism to promote ACP activation on altered host cells and facilitate their destruction.

We have used liposomes containing LPS chemotypes of known structure and activating phospholipids to further analyze the functions of DAF and H on C3b bound to ACP activators. The shortest LPS studied from serotype Re595 failed to activate the ACP or to regulate DAF or H activity. The failure of Re595 LPS to affect DAF function indicates that the insertion of lipid A into the membrane does not interfere with the function of GPI-anchored DAF. The presence of the additional disaccharide made up of two L-glycero-D-mannoheptose residues in the R7 mutant was sufficient to result in ACP activation in serum. DAF was a poor regulator of C3bBb on liposomes containing R7 or larger LPS molecules, and there was no difference in DAF regulatory activity for the different-length LPS (Fig. 3).

H activity was also decreased on liposomes containing R7, R5, and wild type LPS but not by 3-deoxy-D-manno-octulosonic acid-lipid A. Results obtained with H differed from those obtained with DAF in that decreased H function correlated with increasing LPS length (Fig. 4). The R7 mutant consistently restricted DAF function but was ineffective in limiting H (Fig. 5). The R5 LPS, in which glucose is attached to two L-glycero-D-mannoheptose residues, and especially the wild-type LPS molecules were more effective than R7 in inhibiting H but equivalent to R7 in their effects on DAF. Thus, H is able to discriminate among LPS structures, consistent with its role in regulating ACP activation by microorganisms. Pangburn described a similar effect of polysaccharide size on inhibition of H binding to C3b in solution (30). Covalent binding of C3b to a polysaccharide of at least tetrameric size was required, and an interaction between the polysaccharide and an H binding site on C3b was postulated. Although we observed high-molecular-weight bands consistent with covalent binding of ¹²⁵I-C3b to LPS on liposomes after serum incubation, we did not observe these bands after incubation of LPS liposomes with purified components (data not shown). This finding suggests that when both C3b and LPS are bound to the same surface, LPS can affect H activity in the absence of covalent C3b binding to LPS.

Although DAF was a poor regulator of the ACP on liposomes containing LPS, it was able to effectively regulate ACP activation by liposomes containing PE. These liposomes had previously been shown to activate the ACP in serum and to show reduced H binding (23). In the present study, regulation of the assembled ACP convertase, C3bBb, by H was decreased on PE liposomes (Fig. 6). DAF was equally effective in nonactivating PC and activating PE membranes, consistent with its role in preventing complement activation on membrane surfaces. We have previously observed normal DAF function in sickled erythrocytes which activate the ACP due to exposure of PE and phosphatidylserine (42).

The results of our experiments indicate different restriction of H and DAF regulatory function by ACP activators. The mechanism of this restriction is unknown. It is possible that engagement of sites on C3b by molecules on the surface of activators could play a role. The lack of a requirement for C3b covalent binding to LPS and the different effects of PE and R7 on DAF and H make this possibility less likely. In addition, DAF and H show different binding specificities for C3b and C3bBb (9, 28). Alternatively, it is possible that DAF like H have an ability to recognize structures on ACP activators and nonactivators. Further experiments are needed to clarify these issues.

The results presented in this report provide further evidence for the selective inhibition of DAF in membranes containing ACP-activating polysaccharides. However, they point out differences in the recognition of ACP activators by DAF and H consistent with their roles as fluid-phase and membrane regulatory proteins. Selective inhibition of DAF function could be adaptive in that it could help convert virus-infected or transformed human cells expressing new or altered surface molecules to ACP activators, thereby aiding in their elimination.